Cover ImageSALE
市場調查報告書

多發性硬化症(MS) - 市場洞察,流行病學,市場預測 ∼2027年

Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027

出版商 DelveInsight Business Research LLP 商品編碼 602106
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症(MS) - 市場洞察,流行病學,市場預測 ∼2027年 Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027
出版日期: 2018年12月01日 內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的多發性硬化症(MS)市場調查,市場及疾病概要,病型、年齡、綜合障礙度、性別的患病數的變化與預測,各國市場趨勢,上市藥及開發中的治療藥概要,市場成長要素及障礙分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 重要的洞察

第2章 多發性硬化症(MS)市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 多發性硬化症(MS):疾病背景和概要

  • 簡介
  • 症狀
  • 病型
  • 風險因素
  • 原因
  • 病因
  • 診斷

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家的患病數
  • 主要7個國家的患病數:各地區
  • 主要7個國家的患病數(實數)
  • 主要7個國家的患病數(預測數)

第5章 美國的多發性硬化症(MS)市場

  • 美國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)

第6章 歐盟5國的多發性硬化症(MS)市場

  • 德國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 法國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 義大利
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 西班牙
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 英國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)

第7章 日本的多發性硬化症(MS)市場

  • 患病數
  • 患病數:性別
  • 患病數:病型
  • 患病數:各年齡
  • 患病數:各綜合障礙度(EDSS)

第8章 治療

  • 英國神經學會:多發性硬化症(MS)修訂指南

第9章 未滿足需求

第10章 已上市治療藥

  • Betaferon:Bayer Healthcare
    • 醫藥品簡介
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Rebif:Merck KGA
  • Copaxone:Teva Pharmaceutical
  • Avonex:Biogen Idec. Limited
  • Tysabri:Biogen Idec. Limited
  • Fampyra/Ampyra:Acorda Therapeutics/ Biogen Idec Ltd.
  • Gilenya:Novartis
  • Aubagio:Genzyme
  • Tecfidera:Biogen Idec Ltd.
  • Plegridy:Biogen Idec Ltd.
  • Lemtrada:Genzyme
  • Zinbryta:Biogen Idec
  • Ocrevus:Genentech
  • Mavenclad:Merck

第11章 新藥

  • Key Cross Competition
  • 第三階段試驗藥
    • ALKS 8700:Biogen
    • Ublituximab:TG Therapeutics
    • Ozanimod:Celgene Corporation
    • OMB157:Novartis
    • MD1003:MedDay Pharma
    • Masitinib:AB Science
    • Siponimod:Novartis
    • Ponesimod:Johnson & Johnson
    • Evobrutinib:Merck
    • ADS-5102:Adamas Pharmaceuticals

第12章 主要7個國家市場分析

  • 主要的觀察

第13章 市場規模的變化與預測:各國

  • 市場規模:各治療藥物
  • 市場佔有率:各給藥途徑
  • 市場佔有率:各給藥途徑

第14章 美國市場預測

  • 市場規模:各治療藥物

第15章 歐盟5國市場預測

  • 市場規模:各治療藥物

第16章 日本市場預測

  • 市場規模:各治療藥物

第17章 成本分析

第18章 競爭情形

第19章 市場成長要素

第20章 市場障礙

第21章 附錄

  • 調查方法

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0319

DelveInsight's Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Multiple Sclerosis (MS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Multiple Sclerosis (MS) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Multiple Sclerosis (MS) Disease Understanding and Treatment Algorithm

Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis (MS), body's own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.

There are four major categories in Multiple Sclerosis (MS). These are: Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.

Multiple Sclerosis (MS) individuals may experience a variety of symptoms, physically, emotionally, mentally and psychologically. The severity and types of symptoms differ among the individuals; thus symptoms differ among different people.

The DelveInsight Multiple Sclerosis (MS) market report gives the thorough understanding of the MS by including details such as disease definition, types, symptoms, risk factors, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Multiple Sclerosis (MS) in the US, Europe, and Japan.

Multiple Sclerosis (MS) Epidemiology:

The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Population of Multiple Sclerosis (MS), Sex-Specific Prevalence of Multiple Sclerosis (MS), Sub-type Specific Prevalence of Multiple Sclerosis (MS), Age-Specific Prevalence of Multiple Sclerosis (MS) and Prevalence of Multiple Sclerosis (MS) based on EDSS Score] scenario of Multiple Sclerosis (MS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to DelveInsight, total prevalent population of Multiple Sclerosis (MS) in 7 major markets is estimated approximately 1,980,782 in 2016 and it is expected to be increase in forecasted period 2016-2027. It is also estimated that, with the higher prevalence of Multiple Sclerosis (MS) in United States with 1,301,558 prevalent population in 2016 will also increase in 2027.

Multiple Sclerosis (MS) Drug Chapters:

This segment of the Multiple Sclerosis (MS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there are some FDA approved therapies for the treatment of Multiple Sclerosis (MS) include-Betaferon (Bayer Healthcare), Rebif (Merck KGA), Copaxone (Teva Pharmaceutical), Avonex (Biogen), Tysabri (Biogen), Fampyra/Ampyra (Acorda Therapeutics/ Biogen), Gilenya (Novartis), Aubagio (Genzyme), Tecfidera (Biogen), Plegridy (Biogen), Lemtrada (Genzyme), Zinbryta (Biogen) , Ocrevus (Genentech), Mavenclad (Merck).

Apart from all these approved products, there are few promising candidates in the pivotal stage of clinical development, which are expected to boom the market size of Multiple Sclerosis (MS) during our forecast period (2018-2027). These emerging drugs mainly include Siponimod (BAF312; Novartis), Ponesimod (ACT-128800; Johnson and Johnson), Ozanimod (RPC1063; Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), Gocovri (Adamas Pharmaceuticals), Evobrutinib (Merck KgaA) and Mavenclad (Merck KgaA).

Multiple Sclerosis (MS) Market Outlook:

The Multiple Sclerosis (MS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Multiple Sclerosis (MS) in 7MM was found to be USD 21,248 million in 2016, and is expected to increase in 2027.

According to DelveInsight, the United States accounts for the largest market size of Multiple Sclerosis (MS), in comparison to the other 7 MM countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Multiple Sclerosis (MS) Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Sclerosis (MS) Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Multiple Sclerosis (MS) Report Key Strengths:

  • 10 Years Forecast
  • 7MMCoverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple Sclerosis (MS) Report Assessment:

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Multiple Sclerosis (MS) market
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis (MS) (MS) market
  • To understand the future market competition in the Multiple Sclerosis (MS) market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report.

Table of Contents

1. Key Insights

2. Multiple Sclerosis (MS) Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Multiple Sclerosis (MS) in 2016
  • 2.2. Market Share (%) Distribution of Multiple Sclerosis (MS) in 2027

3. Multiple Sclerosis (MS): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Types of Multiple Sclerosis (MS)
  • 3.4. Risk Factors
  • 3.5. Causes
  • 3.6. Pathogenesis
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Prevalent Population of Multiple Sclerosis (MS)
  • 4.4. Prevalent Population of Multiple Sclerosis (MS) in 7MM - By Region
  • 4.5. Prevalent Population of Multiple Sclerosis (MS) in 7MM - Distribution (2016)
  • 4.6. Prevalent Population of Multiple Sclerosis (MS) in 7MM - Distribution (2027)

5. Country Wise-Epidemiology of Multiple Sclerosis (MS)

  • 5.1. United States
    • 5.1.1. Prevalent Population of Multiple Sclerosis (MS) in the United States
    • 5.1.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in the United States

6. EU5 Countries

  • 6.1. Germany
    • 6.1.1. Prevalent Population of Multiple Sclerosis (MS) in Germany
    • 6.1.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Germany
  • 6.2. France
    • 6.2.1. Prevalent Population of Multiple Sclerosis (MS) in France
    • 6.2.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in France
  • 6.3. Italy
    • 6.3.1. Prevalent Population of Multiple Sclerosis (MS) in Italy
    • 6.3.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Italy
  • 6.4. Spain
    • 6.4.1. Prevalent Population of Multiple Sclerosis (MS) in Spain
    • 6.4.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Spain
    • 6.4.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Spain
    • 6.4.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.4.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Spain
  • 6.5. United Kingdom
    • 6.5.1. Prevalent Population of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in United Kingdom

7. Japan

  • 7.1. Prevalent Population of Multiple Sclerosis (MS) in Japan
  • 7.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Japan

8. Treatment

  • 8.1. Association of British Neurologists: Revised Guidelines for prescribing disease-modifying treatments in Multiple Sclerosis (MS) (2016)
  • 8.2. Overcoming barriers in Progressive Multiple Sclerosis (MS) treatment

9. Unmet Needs

10. Marketed Drugs

  • 10.1. Betaferon: Bayer Healthcare
    • 10.1.1. Drug Description
    • 10.1.2. Mechanism of Action
    • 10.1.3. Regulatory Milestones
    • 10.1.4. Advantages & Disadvantages
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Rebif: Merck KGA
    • 10.2.1. Drug Description
    • 10.2.2. Mechanism of Action
    • 10.2.3. Regulatory Milestones
    • 10.2.4. Advantages & Disadvantages
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. Copaxone: Teva Pharmaceutical
    • 10.3.1. Drug Description
    • 10.3.2. Mechanism of action
    • 10.3.3. Regulatory Milestones
    • 10.3.4. Advantages & Disadvantages
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile
  • 10.4. Avonex: Biogen Idec. Limited
    • 10.4.1. Drug Description
    • 10.4.2. Mechanism of action
    • 10.4.3. Regulatory Milestones
    • 10.4.4. Advantages & Disadvantages
    • 10.4.5. Safety and efficacy
    • 10.4.6. Product Profile
  • 10.5. Tysabri: Biogen Idec. Limited
    • 10.5.1. Drug Description
    • 10.5.2. Mechanism of action
    • 10.5.3. Regulatory Milestones
    • 10.5.4. Advantages & Disadvantages
    • 10.5.5. Safety and efficacy of Tysabri
    • 10.5.6. Product Profile
  • 10.6. Fampyra/Ampyra: Acorda Therapeutics/ Biogen Idec Ltd.
    • 10.6.1. Drug Description
    • 10.6.2. Mechanism of action
    • 10.6.3. Regulatory Milestones
    • 10.6.4. Advantages & Disadvantages
    • 10.6.5. Safety and efficacy
    • 10.6.6. Product Profile
  • 10.7. Gilenya: Novartis
    • 10.7.1. Drug Description
    • 10.7.2. Mechanism of action
    • 10.7.3. Regulatory Milestones
    • 10.7.4. Advantages & Disadvantages
    • 10.7.5. Safety and efficacy of Gilenya
    • 10.7.6. Product Profile
  • 10.8. Aubagio: Genzyme
    • 10.8.1. Drug Description
    • 10.8.2. Mechanism of action
    • 10.8.3. Regulatory Milestones
    • 10.8.4. Advantages & Disadvantages
    • 10.8.5. Safety and efficacy
    • 10.8.6. Product Profile
  • 10.9. Tecfidera: Biogen Idec Ltd.
    • 10.9.1. Drug Description
    • 10.9.2. Mechanism of action
    • 10.9.3. Regulatory Milestones
    • 10.9.4. Advantages & Disadvantages
    • 10.9.5. Safety and efficacy
    • 10.9.6. Product Profile
  • 10.10. Plegridy: Biogen Idec Ltd.
    • 10.10.1. Drug Description
    • 10.10.2. Mechanism of action
    • 10.10.3. Regulatory Milestones
    • 10.10.4. Advantages & Disadvantages
    • 10.10.5. Safety and efficacy
    • 10.10.6. Product Profile
  • 10.11. Lemtrada: Genzyme
    • 10.11.1. Drug Description
    • 10.11.2. Mechanism of action
    • 10.11.3. Regulatory Milestones
    • 10.11.4. Advantages & Disadvantages
    • 10.11.5. Safety and efficacy
    • 10.11.6. Product Profile
  • 10.12. Zinbryta: Biogen Idec
    • 10.12.1. Drug Description
    • 10.12.2. Mechanism of action
    • 10.12.3. Regulatory Milestones
    • 10.12.4. Advantages & Disadvantages
    • 10.12.5. Safety and efficacy
    • 10.12.6. Product Profile
  • 10.13. Ocrevus: Genentech
    • 10.13.1. Drug Description
    • 10.13.2. Mechanism of action
    • 10.13.3. Regulatory Milestones
    • 10.13.4. Advantages & Disadvantages
    • 10.13.5. Safety and efficacy
    • 10.13.6. Product Profile
  • 10.14. Mavenclad: Merck
    • 10.14.1. Drug Description
    • 10.14.2. Mechanism of action
    • 10.14.3. Regulatory Milestones
    • 10.14.4. Safety and efficacy
    • 10.14.5. Advantages & Disadvantages
    • 10.14.6. Product Profile

11. Emerging Drugs

  • 11.1. Key Cross Competition
  • 11.2. Phase III Drugs
    • 11.2.1. ALKS 8700: Biogen
      • 11.2.1.1. Other development activities
      • 11.2.1.2. Clinical Development
      • 11.2.1.3. Clinical Trials Information
      • 11.2.1.4. Safety and Efficacy
      • 11.2.1.5. Advantages and Disadvantages
      • 11.2.1.6. Product Profile
    • 11.2.2. Ublituximab: TG Therapeutics
      • 11.2.2.1. Other development activities
      • 11.2.2.2. Clinical Development
      • 11.2.2.3. Clinical Trials Information
      • 11.2.2.4. Safety and Efficacy
      • 11.2.2.5. Advantages and Disadvantages
      • 11.2.2.6. Product Profile
    • 11.2.3. Ozanimod: Celgene Corporation
      • 11.2.3.1. Other development activities
      • 11.2.3.2. Clinical Development
      • 11.2.3.3. Clinical Trials Information
      • 11.2.3.4. Safety and Efficacy
      • 11.2.3.5. Advantages and Disadvantages
      • 11.2.3.6. Product Profile
    • 11.2.4. OMB157: Novartis
      • 11.2.4.1. Other development activities
      • 11.2.4.2. Clinical Development
      • 11.2.4.3. Clinical Trials Information
      • 11.2.4.4. Safety and Efficacy
      • 11.2.4.5. Advantages and Disadvantages
      • 11.2.4.6. Product Profile
    • 11.2.5. MD1003: MedDay Pharma
      • 11.2.5.1. Other development activities
      • 11.2.5.2. Clinical Development
      • 11.2.5.3. Clinical Trials Information
      • 11.2.5.4. Safety and Efficacy
      • 11.2.5.5. Advantages and Disadvantages
      • 11.2.5.6. Product Profile
    • 11.2.6. Masitinib: AB Science
      • 11.2.6.1. Other regulatory milestone
      • 11.2.6.2. Clinical Development
      • 11.2.6.3. Clinical Trials Information
      • 11.2.6.4. Safety and Efficacy
      • 11.2.6.5. Advantages and Disadvantages
      • 11.2.6.6. Product Profile
    • 11.2.7. Siponimod: Novartis
      • 11.2.7.1. Other development activities
      • 11.2.7.2. Clinical Development
      • 11.2.7.3. Clinical Trials Description
      • 11.2.7.4. Safety and Efficacy
      • 11.2.7.5. Advantages and Disadvantages
      • 11.2.7.6. Product Profile
    • 11.2.8. Ponesimod: Johnson & Johnson
      • 11.2.8.1. Other regulatory milestones
      • 11.2.8.2. Clinical Development
      • 11.2.8.3. Clinical Trials Description
      • 11.2.8.4. Safety and Efficacy
      • 11.2.8.5. Advantages and Disadvantages
      • 11.2.8.6. Product Profile
    • 11.2.9. Evobrutinib: Merck
      • 11.2.9.1. Product Description
      • 11.2.9.2. Other Developmental Activities
      • 11.2.9.3. Clinical Development
      • 11.2.9.4. Safety and Efficacy
      • 11.2.9.5. Product Profile
    • 11.2.10. ADS-5102: Adamas Pharmaceuticals
      • 11.2.10.1. Product Description
      • 11.2.10.2. Other Developmental Activities
      • 11.2.10.3. Clinical Development
      • 11.2.10.4. Safety and Efficacy
      • 11.2.10.5. Product Profile

12. Multiple Sclerosis (MS): 7 Major Market Analysis

  • 12.1. Key Findings

13. Global Market Size by Therapies

  • 13.1. Global Market Size by Line of Therapies
  • 13.2. Global Market Share of Therapies by Route of Administration (RoA)
  • 13.3. Global Market Size by Route of Administration (RoA)

14. The United States Market Outlook

  • 14.1. Market Size by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Market Size of MS by Therapies in EU5

16. Japan-MS Market Size

17. Cost Analysis of Multiple Sclerosis (MS)

18. Generic Competition in MS Market

19. Market Drivers

20. Market Barriers

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: Characteristics of MS Subtypes
  • Table 2: The 2010 revised McDonald criteria for diagnosis of MS
  • Table 3: Total Prevalent Population of Multiple Sclerosis (MS) in 7 MM (2016-2027)
  • Table 4: Prevalent Population of Multiple Sclerosis (MS) in 7MM- By Region (2016-2027)
  • Table 5: Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 6: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 7: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 8: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 9: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in United States (2016-2027)
  • Table 10: Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 11: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 12: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 13: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 14: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Germany (2016-2027)
  • Table 15: Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 16: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 17: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 18: Age Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 19: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in France (2016-2027)
  • Table 20: Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 21:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 22:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 23:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 24: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Italy (2016-2027)
  • Table 25:Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 26:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 27:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 28:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 29:Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Spain (2016-2027)
  • Table 30:Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 31:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 32:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 33:Age Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 34:Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in United Kingdom (2016-2027)
  • Table 35:Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 36:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 37:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 38:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 39: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Japan (2016-2027)
  • Table 40:Medications for the treatment of MS
  • Table 41: Comparison of emerging drugs (Immunomodulators) under development
  • Table 42: Comparison of emerging drugs (other classes) under development
  • Table 43: ALKS 8700 Clinical Trial Description, 2018
  • Table 44: Ublituximab, Clinical Trial Description, 2018
  • Table 45: RPC1063, Clinical Trial Description, 2018
  • Table 46: Ofatumumab, Clinical Trial Description, 2018
  • Table 47: MD1003, Clinical Trial Description, 2018
  • Table 48: Masitinib, Clinical Trial Description, 2018
  • Table 49: BAF312, Clinical Trial Description, 2018
  • Table 50: Ponesimod, Clinical Trial Description, 2018
  • Table 51: Evobrutinib, Clinical Trial Description, 2018
  • Table 52: ADS-5102, Clinical Trial Description, 2018
  • Table 53: Global Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 54: Global Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 55: Global Market Share of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Table 56: Global Market Size of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Table 57: Global Market share of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Table 58: Global Market size of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Table 59: The US Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 60: The US Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 61: EU5 Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 62: EU5 Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 63: Germany Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 64: France Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 65: Italy Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 66: UK Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 67: UK Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 68: Japan Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 69:Japan Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)

List of Figures

  • Figure 1: Types of Multiple Sclerosis (MS)
  • Figure 2: Risk factors for Multiple Sclerosis (MS)
  • Figure 3: The immunological complexity of the immune/cytokine network in Multiple Sclerosis (MS)
  • Figure 4: Total Prevalent Population of Multiple Sclerosis (MS) in 7 MM (2016-2027)
  • Figure 5: Prevalent Population of Multiple Sclerosis (MS) in 7MM- By Region (2016-2027)
  • Figure 6: Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 9: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 10: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in US (2016-2027)
  • Figure 11: Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 14: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 15: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Germany (2016-2027)
  • Figure 16: Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 19: Age Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 20: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in France (2016-2027)
  • Figure 21: Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 24: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 25: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Italy (2016-2027)
  • Figure 26: Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 29: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 30: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Spain (2016-2027)
  • Figure 31: Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 34: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 35: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in UK (2016-2027)
  • Figure 36: Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 39: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 40: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Japan (2016-2027)
  • Figure 41: Treatment algorithm for Multiple Sclerosis (MS)
  • Figure 42: Diagnosis and Therapy selection
  • Figure 43: Unmet Needs of Multiple Sclerosis (MS) Disease
  • Figure 44: Global Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 45: Global Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027
  • Figure 46: Global Market Share of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Figure 47: Global Market Size of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2025)
  • Figure 48: Global Market share of Multiple Sclerosis (MS) (MS) therapies by RoA (2016 & 2027)
  • Figure 49: Global Market size of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Figure 50: The US Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 51: The US Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Figure 52: EU5 Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 53: EU5 Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2015-2025)
  • Figure 54: Germany Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 55: France Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 56: Italy Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 57: Spain Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 58: UK Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 59: Japan Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2015-2025)
  • Figure 60: Japan Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2015-2025)
  • Figure 61: Market Drivers
  • Figure 62:Market Barriers
Back to Top